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Abstract
Skin toxicity is a common side-effect of treatment with imatinib mesylate (STI571, Glivec
TM) in advanced gastrointestinal
stromal tumours (GIST) and chronic myeloid leukaemia. The optimal duration of treatment with imatinib mesylate in
GIST has not yet been established, as durable remissions have been observed in patients. It is, therefore, important to
develop strategies to deal with common side-effects of what may be a long-term treatment. Here we report the case of a
patient with advanced GIST who developed a cutaneous drug reaction secondary to imatinib mesylate and the various
management options that may be employed depending upon the severity of the toxicity. The case and literature are
discussed.
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Case report
A 66-year-old male was originally diagnosed with a
gastrointestinal stromal tumour in 2002. The tumour
was macroscopically completely excised at laparot-
omy. He remained well on follow-up for 18 months.
He then developed further symptoms. CT scanning
confirmed a large mesenteric and omental recur-
rence. In March 2004 he was, therefore, commenced
on the tyrosine kinase inhibitor imatinib mesylate
(STI 571, Glivec) 400mg daily. As his past medical
history included hypertension, stroke, type II
diabetes mellitus and osteoarthritis, he was on a
number of medications including amlodipine 5mg
od, metformin 500mg bd and lansoprazole 15mg
od, all of which he had been taking for several years.
He had no history of drug allergy.
He tolerated the first 8 weeks of treatment with
imatinib well, the only toxicities were grade I
periorbital oedema and diarrhoea. He was started
on loperamide. Follow-up CT scanning at this stage
confirmed a good disease response.
At review 4 weeks later the grade I periorbital
oedema persisted, but he now had grade II
diarrhoea. He had, also, developed a grade I
maculopapular rash affecting both forearms, which
was felt may be related to either the loperamide or
imatinib. As the rash had developed shortly after the
loperamide was commenced, the decision was made
to discontinue this, and he was changed to codeine
phosphate.
However, the rash continued to progress and was
exacerbated by exposure to sunlight. When he
attended for follow-up at the outpatients’ clinic, he
was found to have a grade 3 erythematous, maculo-
papular rash affecting the torso and limbs. The rash
was causing significant discomfort and itch. His full
blood count at this time showed a moderate
eosinophilia of 2.06 (normal range 0.04–0.40). On
the advice of the dermatology department he was
prescribed Elocon ointment (mometasone furorate)
and continued on the same dose of imatinib. A dose
reduction of the imatinib was considered at this time,
but there were concerns about the risk of tumour
flare and, therefore, the decision was made to
continue on the current dose of imatinib, but to
closely monitor the response to topical steroids.
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his symptoms had improved slightly with decreased
erythema and itch. However, on examination he
continued to have a widespread excoriated dermatitis
affecting the trunk and limbs with areas of sparing
in the skin folds and axillae (see Figure 1). As the
patient had shown some response to a moderately
potent topical steroid, a more potent topical steroid,
dermovate (clobetasol propionate) was started as
well as an oral antihistamine, chlorpheniramine. He
was also encouraged to use plenty of emollients.
Despite applying the more potent topical steroid
daily, the rash continued to cause significant
symptoms. He was, therefore advised to increase to
twice daily applications of dermovate to the trunk
and apply eumovate to the face and neck lesions.
A skin biopsy was also performed, which showed
interphase dermatitis with numerous prominent
clusters of colloid bodies in keeping with a drug
reaction (Figure 2).
The patient has continued with twice daily
applications of the steroid creams, with improvement
in the appearance and symptoms from the rash
(now grade I) and his eosinophil count is back
within the normal range (0.15). He has not required
a dose reduction or interruption of imatinib.
However, if the rash had failed to respond rapidly
to topical steroids a short drug holiday followed by
gradual re-introduction of imatinib would have been
initiated.
Discussion
Soft-tissue sarcomas represent 1% of adult malig-
nancies and are derived from mesenchymal tissue.
Management options include surgery, radiotherapy
and chemotherapy. Gastrointestinal stromal tumours
are a sub-type of sarcoma that have a different
natural history [1]. They arise predominantly in the
stomach (60%) and small intestine (25%), but can
arise at a number of other locations including
oesophagus, rectum, appendix, gallbladder, pan-
creas, mesentery, omentum and retroperitoneum.
The peak age of occurrence is 60 years (range second
to tenth decade). The tumours can be anything
between 2 and 30cm at time of diagnosis and may
only be discovered incidentally [2]. Patients with
metastatic or locally advanced GIST tumours have
limited treatment options, as responses to conven-
tional chemotherapy are very poor with reported
objective response rates of <5%.
Imatinib mesylate (STI 571, Glivec) is a small
molecule tyrosine kinase inhibitor designed to target
c-ABL and BCR-ABL, but is also able to target KIT
and platelet-derived growth factor receptor
(PDGFR). KIT is highly expressed in GIST
1 and
the KIT proto-oncogene is often mutated resulting in
activation of the kinase. Although KIT expression is
not strictly specific, it is highly suggestive of a
diagnosis of GIST for sarcomas arising in the
digestive tract or abdomen. PDGFR is widely
expressed in mesenchymal tissues and the majority
of soft-tissue sarcoma sub-types.
A phase I study identified the recommended dose
of imatinib as 400mg twice daily and this dose level
had significant activity with objective response
rates of 69% and symptomatic benefit in 89% [3].
Phase II studies of imatinib demonstrated that 71%
of patients had an objective response and 73%
Figure 1. Widespread, erythematous, maculopapular skin rash.
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1 year [4].
The optimal duration of therapy is not yet clear
due to the durable remissions observed in patients.
As imatinib may be given for long periods it is
important to fully characterise the side-effect profile
and develop mechanisms for managing toxicities that
may arise. Trials of imatinib in GIST to date [4] have
shown the most frequent side effects to be anaemia
(92%), periorbital oedema (84%), skin rash (69%),
fatigue (76%), nausea (57%), granulocytopenia
(47%), and diarrhoea (47%). The toxicities are
generally mild, grade 1 or 2 severity (NCI-CTC).
Standard management of cutaneous drug reac-
tions usually entails withdrawal of the suspected drug
and avoidance of further exposure to this drug in the
future. However, in patients with GIST, responses to
conventional chemotherapy are very poor, therefore,
oncologists (and patients) are keen to avoid perma-
nent withdrawal of imatinib, unless there is no other
option.
Skin rashes associated with imatinib usually occur
soon after commencing therapy, but may develop
many months later. The typical rash is maculopap-
ular and puritic and is distributed predominantly
over the forearms, trunk, legs and face [5]. The
rash is more likely to occur with higher doses
(>600mg/day) and therefore, may be a pharmacolo-
gical effect rather than just a hypersensitivity reac-
tion. The majority of these rashes are self-limiting
and easily treated with emollients and topical
steroids. Usually the patient can continue on the
same dose of imatinib. More severe cases may
require oral steroids and a dose interruption until
the rash has improved to grade I, then a re-challenge
with imatinib at a lower dose level (50–100mg/day)
with steroid cover and a gradual dose escalation. The
oral steroid dose is usually starting in the range of
0.5–1.0mg/kg per day of prednisolone or equivalent.
Imatinib is predominantly metabolised in the liver
by the CYP3A4/5 p450 enzyme system. Gluco-
corticoids and dexamethasone are potential inducers
of this enzyme system and their use could therefore
theoretically result in decreased levels of imatinib
[5]. However, dose reduction or interruption is
usually required in patients with skin toxicity severe
enough to require oral steroids. Lansoprazole has
been shown in vitro to be a potent inhibitor of the
cytochrome p450 system [6] and, therefore, it is
theoretically possible that this may have resulted in
altered pharmacokinetics of imatinib in this patient.
Occasionally the rash can progress to erythro-
derma which constitutes grade 4 toxicity. This
requires immediate and permanent cessation of
imatinib and supportive treatment including oral
and topical steroids [7]. However, in patients with
GIST, there are concerns about sudden withdrawal
of imatinib as GIST-disease reactivation after cessa-
tion of imatinib therapy has been demonstrated by
[
18F]fluorodeoxyglucose (FDG)-PET scanning. In
comparison with CT, FDG-PET reports responses
in most patients within 1 week of commencing
imatinib, whereas CT scanning may only reveal
responses after 2–3 months. Within days of
Figure 2. Skin biopsy demonstrating interphase dermatitis.
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sponding to the tumour mass become significantly
enhanced, suggesting that the tumour cells have
reactivated and this may have clinical significance for
the patient in terms of symptom control, risk of
haemorrhage into the tumour and other complica-
tions [8]. However, only a few cases will have skin
toxicity severe enough to warrant definitive drug
discontinuation.
With regards to the eosinophilia observed in this
case, the incidence of eosinophilia in patients on
drug therapy is probably less than 0.1%. There is an
extensive list of drugs capable of producing skin
toxicity and eosinophilia that do not seem to have
common chemical or pharmacological properties.
In cases where eosinophilia secondary to drug
hypersensitivity is suspected on clinical grounds,
stopping the drug usually resolves the problem.
When an important drug is suspected to be the
cause of the hypersensitivity reaction a re-challenge
can be attempted. In this situation, the eosinophilic
reaction should reappear within 10 days if it is
secondary to the suspected drug [9].
Conclusion
Skin rashes are a common side effect of imatinib.
They are, however, usually mild and self-limiting and
do not require dose interruption. They generally
respond to topical steroids, emollients and anti-
histamines, but may occasionally require oral
steroids. More severe cases may require dose
reduction or interruption until the rash has improved
to grade I, and re-challenge of imatinib at a lower
dose (50–100mg/day) with steroid cover and gradual
escalation in the dose of imatinib. In cases of severe,
grade 4 skin rash, re-challenge is not recommended.
In the case reported, the patient developed grade
III skin toxicity related to the use of imatinib.
This responded well to the use of topical steroids,
but, in retrospect, an earlier drug reduction or
interruption may have prevented the rash from
becoming so severe and consequently requiring
potent topical steroids for resolution.
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